Healthy Returns: What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
Tom Little | Reuters A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn't catching a break this year. Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed to match the weight loss of Eli Lilly 's Zepbound in a phase three trial. The results showed that Novo's drug, CagriSema, promoted slightly less weight loss than Zepbound at 84 weeks in the study — a difference that puts the sales potential of the experimental treatment into question. Analysts all raise the same point: Why would patients or doctors choose Novo's drug over a more effective and widely-known choice like Zepbound? “We struggle to identify a reason why a patient would be prescribed CagriSema” instead of Zepbound if the product comes to market, said BMO analyst Evan Seigerman in a Monday
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: The New PayPal? [Seeking Alpha]Seeking Alpha
- Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50% [FOX Business Network]FOX Business Network
- Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 [CNN]CNN
- Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 [CNN]CNN
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/23/26 - Form 6-K
- 2/23/26 - Form 6-K
- 2/20/26 - Form 6-K
- NVO's page on the SEC website